Robert R Kauffman Net Worth

The estimated Net Worth of Robert R Kauffman is at least $43.7 Thousand dollars as of 19 November 2012. Robert Kauffman owns over 25,000 units of Perspective Therapeutics Inc stock worth over $43,700 and over the last 17 years Robert sold ISR stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Robert Kauffman ISR stock SEC Form 4 insiders trading

Robert has made over 2 trades of the Perspective Therapeutics Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently Robert bought 25,000 units of ISR stock worth $9,500 on 19 November 2012.

The largest trade Robert's ever made was buying 25,000 units of Perspective Therapeutics Inc stock on 19 November 2012 worth over $9,500. On average, Robert trades about 10,000 units every 103 days since 2007. As of 19 November 2012 Robert still owns at least 113,802 units of Perspective Therapeutics Inc stock.

You can see the complete history of Robert Kauffman stock trades at the bottom of the page.

What's Robert Kauffman's mailing address?

Robert's mailing address filed with the SEC is 7950 E Acoma Dr #111, Scottsdale, AZ 85260, USA.

Insiders trading at Perspective Therapeutics Inc

Over the last 18 years, insiders at Perspective Therapeutics Inc have traded over $0 worth of Perspective Therapeutics Inc stock and bought 1,651,741 units worth $855,397 . The most active insiders traders include Lori A Woods, Thomas C Lavoy, and Dwight William Babcock. On average, Perspective Therapeutics Inc executives and independent directors trade stock every 60 days with the average trade being worth of $14,501. The most recent stock trade was executed by Lori A Woods on 13 April 2023, trading 187,500 units of ISR stock currently worth $114,375.

What does Perspective Therapeutics Inc do?

Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium Blu brachytherapy seeds, which are expanding brachytherapy treatment options throughout the body.

Complete history of Robert Kauffman stock trades at Perspective Therapeutics Inc

Perspective Therapeutics Inc executives and stock owners

Perspective Therapeutics Inc executives and other stock owners filed with the SEC include:

• Lori Woods,
  Chief Executive Officer, Director
• Lori A. Holmes-Woods,
  CEO & Director
• Michael Krachon,
  Executive Vice President of Sales and Marketing
• William Cavanagh,
  Chief Research and Development Officer
• Michael L. Krachon,
  Exec. VP of Sales & Marketing
• Jennifer Streeter,
  COO & VP of HR
• William A. Cavanagh III,
  Chief R&D Officer
• Krista Cline,
  Senior Director of Operations, Corporate Secretary
• Philip Vitale,
  Independent Director
• Alan Hoffmann,
  Independent Director
• Jonathan Hunt,
  Chief Financial Officer, Co-Principal Financial Officer
• Mark Austin,
  Controller, Co-Principal Financial and Principal Accounting Officer
• Jennifer Streeter,
  Chief Operating Officer, Vice President of Human Resources
• Michael McCormick,
  Independent Chairman of the Board
• Krista Cline,
  Sr. Director of Operations & Corp. Sec.
• Mark J. Austin CPA,
  VP of Fin., Controller, Co-Principal Financial, Principal Accounting Officer & Sec.
• Jonathan R. Hunt,
  CFO & Co-Principal Financial Officer
• Frank Morich,
  Director
• Brien Ragle,
  Controller
• Dwight William Babcock,
  CEO
• Matthew Branson,
  Principal Fin & Acct Officer
• Robert F Iii Williamson,
  Director
• Thomas C Lavoy,
  Director
• Albert Louis Smith,
  Director
• Roger Girard,
  CEO/President
• Robert R Kauffman,
  Director
• Fredric Swindler,
  Vice President
• David Swanberg,
  EVP Operations & Secretary
• Stephen Boatwright,
  Director